Clinical trial · Observational
Lenalidomide Monotherapy in R/R DLBCL
An Observational Retrospective Cohort Study of Lenalidomide Monotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) to Generate a Historical Control for Clinical Trial MOR208C203 (RE-MIND)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial MOR208C203 (L-MIND)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Best overall/objective response rate (ORR)
- timeFrame
- Through study completion, an average of 9 months
- description
- Proportion of patients with complete response (CR) or partial response (PR) as best response achieved at any time during the study
Secondary outcomes (3)
- measure
- Overall survival
- timeFrame
- Through study completion, an average of 9 months
- description
- Time from treatment start until death from any cause
- measure
- Complete response rate
- timeFrame
- Through study completion, an average of 9 months
- description
- Proportion of patients having CR based on the best objective response achieved at any time during the study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of DLBCL * Relapsed/refractory to at least one previous systemic therapy for DLBCL * Received at least one, but no more than three previous systemic regimens for the treatment of DLBCL, including at least one anti-CD20 containing therapy * Received lenalidomide monotherapy for R/R DLBCL while being considered not eligible for an ASCT Exclusion Criteria: * CNS involvement by lymphoma * Patients who received lenalidomide in combination with another anti-lymphoma therapy (including radiation) * Previously treated with anti-CD19-targeted therapy or immunomodulatory drugs * Patients who previously underwent allogeneic SCT * Known simultaneous detection of MYC and BCL2 or BCL6 translocation according to FISH * Patients with a history of other malignancies within 5 years prior to lenalidomide treatment start
References
Publications (0)
Data not yet available